GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials

[1]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[2]  M. Farkouh,et al.  Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus , 2017, Cardiovascular Drugs and Therapy.

[3]  M. Farkouh,et al.  The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease , 2017, Cardiovascular Drugs and Therapy.

[4]  K. Khunti,et al.  Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis , 2017, Diabetes, obesity & metabolism.

[5]  Y. Birnbaum,et al.  Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. , 2017, Journal of diabetes and its complications.

[6]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[7]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[8]  John A. Galdo,et al.  Hypoglycemic agents and potential anti-inflammatory activity , 2016, Journal of inflammation research.

[9]  B. Okopień,et al.  Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner , 2016, Pharmacological reports : PR.

[10]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[11]  Lingling Wu,et al.  Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. , 2015, Biochemical and biophysical research communications.

[12]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[13]  The continued importance of optimal medical therapy with or without revascularization in diabetic patients with coronary artery disease. , 2015, Trends in cardiovascular medicine.

[14]  M. Yoshizumi,et al.  Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways , 2015, PloS one.

[15]  I. Dicembrini,et al.  Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists , 2015, Diabetes Therapy.

[16]  K. Khunti,et al.  The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis , 2015, PloS one.

[17]  A. Scheen,et al.  Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. , 2015, Diabetes & metabolism.

[18]  Feng Bai,et al.  Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart , 2015, Cardiovascular Drugs and Therapy.

[19]  J. Mehta,et al.  GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A , 2014, Journal of cardiovascular pharmacology.

[20]  Y. Birnbaum,et al.  Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury , 2014, Journal of cardiovascular pharmacology and therapeutics.

[21]  D. Wootten,et al.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation , 2014, British journal of pharmacology.

[22]  M. Monami,et al.  Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[23]  U. Werner.  Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence. , 2014, Journal of diabetes and its complications.

[24]  Bin Wang,et al.  Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials , 2013, Diabetes, obesity & metabolism.

[25]  P. Doevendans,et al.  Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. , 2013, International journal of cardiology.

[26]  A. Dear,et al.  The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model , 2013, Diabetes & vascular disease research.

[27]  E. Horton,et al.  Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. , 2013, Diabetes research and clinical practice.

[28]  J. Ayala,et al.  Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. , 2013, American journal of physiology. Cell physiology.

[29]  W. Sheu,et al.  Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study , 2013, The Lancet.

[30]  S. Yamagishi,et al.  Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. , 2013, The American journal of pathology.

[31]  J. L. Samaniego,et al.  Erratum to “Characterization of Selective Antibacterial Peptides by Polarity Index” , 2012, International Journal of Peptides.

[32]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[33]  Y. Birnbaum,et al.  Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. , 2012, Metabolic syndrome and related disorders.

[34]  S. Yamagishi,et al.  Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. , 2012, Microvascular research.

[35]  S. Nishikawa,et al.  Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes , 2012, Diabetes.

[36]  H. Yokomizo,et al.  GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. , 2012, Metabolism: clinical and experimental.

[37]  V. Allgar,et al.  A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure , 2012, International journal of peptides.

[38]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[39]  C. Terkelsen,et al.  Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia , 2012, Circulation. Cardiovascular interventions.

[40]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[41]  S. Yamagishi,et al.  Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. , 2011, Metabolism: clinical and experimental.

[42]  J. Holst,et al.  Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. , 2011, The Journal of clinical endocrinology and metabolism.

[43]  P. Hruz,et al.  Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy , 2011, PloS one.

[44]  M. Trautmann,et al.  DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[45]  M. Fineman,et al.  Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing , 2011, Clinical pharmacokinetics.

[46]  S. Miyamoto,et al.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.

[47]  J. Rosenstock,et al.  Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[48]  A. Dear,et al.  A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. , 2009, The Journal of endocrinology.

[49]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[50]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[51]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[52]  D. Yellon,et al.  GLP-1 therapy: beyond glucose control. , 2008, Circulation. Heart failure.

[53]  I. Poornima,et al.  Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat , 2008, Circulation. Heart failure.

[54]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[55]  J. Lim,et al.  Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. , 2007, Journal of the American Society of Nephrology : JASN.

[56]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[57]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.